title: The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study--results from 29 358 German patients.
abstract: We assessed the safety, efficacy and patient acceptability of vardenafil (Levitra, Bayer HealthCare, Leverkusen, Germany) under real-life conditions in patients with erectile dysfunction (ED) in a multinational post-marketing surveillance study. An initial and up to two follow-up visits were documented for 29 358 German ED patients receiving vardenafil. Patients were interviewed about overall treatment success, and individual sexual attempts were evaluated in a patient questionnaire. Overall erectile improvement was reported by 93.9% of physicians, and similar improvement rates were reported for both 10 mg and 20 mg vardenafil dosages. Most patients experienced improved erections after the first (73.6%) or second (88.5%) tablet. Sexual attempts were successful with respect to partner penetration in 94.9% of patients and with respect to maintenance of erection during intercourse in 87.7% of patients. Adverse drug reactions were very rare (1.3% of patients). Vardenafil was highly effective, reliable and well tolerated in ED patients treated under real-life conditions.
authors.affiliation: Klinikum Osnabruck, Osnabruck, Germany.
authors.forename: H
authors.initials: H
authors.lastname: van Ahlen
authors.forename: J
authors.initials: J
authors.lastname: Zumbé
authors.forename: K
authors.initials: K
authors.lastname: Stauch
authors.forename: H
authors.initials: H
authors.lastname: Landen
mesh_terms: D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005858:Germany; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D010410:Penile Erection; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology*; D011446:Prospective Studies; D012449:Safety; D013450:Sulfones / Q000009:adverse effects / Q000494:pharmacology; D011795:Surveys and Questionnaires; D013997:Time Factors; D016896:Treatment Outcome; D014227:Triazines / Q000009:adverse effects / Q000494:pharmacology; D000069058:Vardenafil Dihydrochloride
chemical_list: D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride